Selective inhibition of collagenase-1, gelatinase A, and gelatinase B by chemotherapeutic agents

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 662-664

  Benbow, Ulrike ^a   Maitra, Rangan ^a   Hamilton, Joshua W ^a   Brinckerhoff, Constance E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; COLLAGENASE; COLLAGENASE INHIBITOR; DOXORUBICIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; MITOMYCIN C;

CANCER INVASION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL;

EID: 0032853467     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07755.x     Document Type: Conference Paper

References (5)

1. 1. Rasmussen, H. & P.P. McCann. 1997. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with specific focus on Batimastat and Marimastat. Pharmacol. Ther. 75: 69-77.
2. 2. Matrisian, L.M. 1992. The matrix-degrading metalloproteinases. Bioassays 14: 455-463.
3. 3. Benbow, U. et al. 1999. Selective modulation of collagenase-1 gene expression by the chemotherapeutic agent doxorubicin. Clin. Cancer Res. 5: 203-208.
4. 4. Ihnat, M.A. et al. 1997. Suppression of p-glycoprotein expression and multidrug resistance by DNA crosslinking agents. Clin. Cancer Res. 3: 1339-1346.
5. 5. Albini, A. et al. 1995. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer 61: 121-129.